Traditional Chinese medicinal composition for treating blood group incompatibility haemolytic disease and preparation method thereof

Abstract

The invention discloses a traditional Chinese medicinal composition for treating blood group incompatibility haemolytic disease, and belongs to the field of traditional Chinese medicines. Regarding the existing technical defects of high hepatotoxicity and poor curative effect of a current chemical treatment medicament for treating blood group incompatibility haemolytic disease, the invention provides the traditional Chinese medicinal composition for treating or preventing blood group incompatibility haemolytic disease, which comprises the following raw materials in parts by weight: 10 to 50 parts of burdock, 10 to 20 parts of oriental wormwood, 5 to 20 parts of Chinese angelica, 5 to 15 parts of common yam rhizome, 5 to 10 parts of cape jasmine, 5 to 15 parts poria, 5 to 15 parts of radix pseudostellariae, 1 to 10 parts of ginseng, 5 to 15 parts of medlar, 9 to 15 parts of astragalus, 9 to 15 parts of golden thread, 5 to 15 parts of rhizoma alismatis, 1.5 to 9 parts of radix ophiopogonis, 5.5 to 15 parts of white peony root, 6 to 9 parts of motherwort, and 10 to 15 parts of liquorice. The traditional Chinese medicinal composition has a good treatment effect in the field of treating or preventing blood group incompatibility haemolytic disease, is low in side effect, and has a remarkable clinical popularization value.

Description

technical field [0001] The invention belongs to the field of traditional Chinese medicine, and in particular relates to a traditional Chinese medicine composition for treating blood type incompatibility between mother and infant. Background technique [0002] Maternal-fetal blood group incompatibility (hemolytic disease of the new born, HDN) is an immune hemolytic disease caused by the difference in blood type between mother and fetus. Common in ABO blood group and Rh blood group. The pathogenesis is basically the same. Influenced by immune factors such as blood transfusion, miscarriage, and pregnancy in the past, the pregnant woman produces blood group antibodies against the paternal source, and IgG antibodies can cross the placenta and enter the fetus to destroy red blood cells. The clinical manifestations are miscarriage, stillbirth, heart failure Failure, neonatal hyperbilirubinemia, and even bilirubin encephalopathy have extremely high mortality and neurological sequel...

AI Technical Summary

Problems solved by technology

The traditional treatment methods for maternal-fetal blood group incompatibility mainly include infusion during pregnancy, oral administration of traditional Chinese medicine, postpartum neonatal blue light irradiation, intravenous albumin infusion, and exchange transfusion, and have achieved certain curative effects. Antibody titers and serological indicators have not been significantly improved

Images